Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine Acetate in Post-herpetic Neuralgia
NCT00981227Phase 2Completed
- Sponsor
- BIAL
- Start
- Nov 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of eslicarbazepine acetate in postherpetic neuralgia (PHN) (6 arms), sponsored by BIAL. Primary endpoint: Change in Mean Pain (NRPS) From Baseline to Endpoint at 13 weeks. Started Nov 2007; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT00981227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981227.